StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $130 at Cowen on Nurtec Momentum
July 7, 2021 10:38 AM
Cowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $130.00 (from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Biohaven Pharmaceuticals (BHVN) Gains Following Sales Surge for Migraine Drug NURTEC ODT
July 7, 2021 11:36 AM
Biohaven Pharma (BHVN) Q2 NURTEC ODT Sales Rise to $93M
July 7, 2021 8:53 AM
Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
July 7, 2021 7:00 AM